The Netherlands
Xenikos B.V., founded in 2009 and headquartered in The Netherlands, is a clinical-stage biotechnology company noted for its slogan, "Developing new, innovative immunotherapy medicines that reset the immune system." The company is positioned at the intersection of biotechnology, health and wellness, and life sciences.
Its lead product candidate, T-Guard®, is at the forefront of the company's efforts, currently in Phase 3 development targeting steroid-refractory acute graft-versus-host disease (SR-aGVHD). The potential applications of T-Guard span across various immune conditions, including transplant-related rejection and severe autoimmune diseases, demonstrating the versatility and promise of its mechanism.
Xenikos's recent financial backing includes a €2.50M grant from the European Innovation Council in December 2022. This investment underscores investor confidence in Xenikos's innovative approach to resetting immune systems in critical health scenarios.
